Multiple Ketamine infusion for Treatment Resistant Obsessive Compulsive Disorder- a placebo controlled study
Not Applicable
- Conditions
- Health Condition 1: F42- Obsessive-compulsive disorder
- Registration Number
- CTRI/2022/01/039257
- Lead Sponsor
- Ahana Hospitals LLP
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Participants must be willing to give a written informed consent document;
Participants must fulfill DSM-5 criteria for Obsessive Compulsive Disorder, and should have been resistant to at least 2 SSRI trails of adequate dose and duration and psychotherapy.
Participants must be medically and neurologically healthy.
Exclusion Criteria
Those who have neurological disorders, severe medical illness, mental retardation and co-morbid psychiatric diagnoses such as psychosis, substance dependence
Women who are pregnancy or breastfeeding
Those who are allergic to ketamine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome measures were (i) a reduction in illness severity on the YBOCS scale compared to baseline scores, and (ii) response [as defined <br/ ><br>by â?¥35 % reduction (response) and 25â??35 % reduction (partial response)] on the YBOCS total score.Timepoint: at baseline, 2 weeks, 4 weeks
- Secondary Outcome Measures
Name Time Method Outcome measures were a reduction in depression severity on the HAM-D scale compared to baseline scores.Timepoint: at baseline, 2 weeks, 4 weeks